Articles tagged with Dendritic Cells
Researchers at Rockefeller University have developed a method to trigger a potent immune response in humans using mature dendritic cells, which lasts for months. The technique shows promise as a new way to fight cancers and chronic infections like HIV.
A University of Michigan cancer vaccine combination with interleukin-2 was found to be effective in mobilizing the immune system to attack and destroy malignant cells. Eighty percent of mice showed complete regression of their tumors after treatment.
Researchers have tested a new approach to immunization, using dendritic cells to stimulate immunity in mice. The technique, which uses heat-killed bacteria to sensitize immune cells, has shown promising results in preventing Chlamydia and potentially HIV infections.
Researchers at the University of Michigan have developed a vaccine made from dendritic cells that triggers the immune system to attack malignant tumors and prevent new tumor development in mice. The study found significant results, including a 70% kill rate of sarcoma cells within four hours.
Researchers at Duke University Medical Center have developed a novel vaccine that uses RNA and dendritic cells to target cancer cells. The vaccine stimulates an immediate and sustained assault on human cells in test tube experiments, showing promise as a universal cancer vaccine.
Researchers from Rockefeller University have developed a new method to fight cancer by using dendritic cells to activate T cells. This technique offers the promise of new therapies for cancer, AIDS, and autoimmune diseases, potentially overcoming the need for designer immunotherapy.
Research by Dr Lanzavecchia reveals that dendritic cells need inflammation to effectively stimulate an immune response. The study also shows that chemical messengers guide immune cells to the target site, enabling the development of new anti-allergy drugs and improved vaccine delivery.
Researchers are developing a new approach to treat cancer by boosting the immune system using dendritic cells, which can be grown in large quantities in culture. The therapy has shown promise in clinical trials, particularly for patients with advanced melanoma or breast cancer.
Researchers at the University of Pennsylvania Medical Center have devised a unique procedure to transform monocytes into battle-ready dendritic cells, boosting the immune system's cancer-fighting forces. The modified cells have shown ability to activate T cells within one week.